Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.155
-0.035 (-2.94%)
Aug 28, 2026, 2:22 PM EDT - Market open
Milestone Pharmaceuticals Revenue
Milestone Pharmaceuticals had revenue of $559.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $2.34M. In the year 2025, Milestone Pharmaceuticals had annual revenue of $1.55M.
Revenue (ttm)
$2.34M
Revenue Growth
n/a
P/S Ratio
71.57
Revenue / Employee
$61,658
Employees
38
Market Cap
162.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| MediWound | 11.86M |
| Caribou Biosciences | 10.04M |
| Equillium | 4.39M |
| NRx Pharmaceuticals | 3.39M |
| Molecular Partners AG | 856.30K |
| Outlook Therapeutics | -1.16M |
MIST News
- 1 day ago - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes - GlobeNewsWire
- 7 days ago - Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial - TheFly
- 7 days ago - Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - GlobeNewsWire
- 8 days ago - Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside - TheFly
- 8 days ago - Milestone Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald - TheFly
- 11 days ago - Milestone Pharmaceuticals reports Q2 EPS (21c), consensus (19c) - TheFly
- 16 days ago - Milestone Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 16 days ago - Milestone Pharmaceuticals Quarterly report: Q2 2026 - Filings